ABBV Jun 2024 80.000 put
| Previous Close | 1.3500 |
| Open | 1.3500 |
| Bid | 0.8100 |
| Ask | 1.2400 |
| Strike | 80.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 1.3500 - 1.3500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 239 |
ZacksHere is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Motley FoolIs AbbVie or Amgen the Better Bargain Buy Right Now?
Due to the highly competitive nature of the pharmaceutical industry, it is no easy task to replace the aging stars in a drug portfolio. Teva Pharmaceutical (NYSE: TEVA) illustrates this point nicely. In the middle of the last decade, Teva lost exclusivity for its multiple sclerosis medication Copaxone.
Simply Wall St.AbbVie Insiders Sell US$8.4m Of Stock, Possibly Signalling Caution \
Over the past year, many AbbVie Inc. ( NYSE:ABBV ) insiders sold a significant stake in the company which may have...
ZacksVertex (VRTX) Stock Poised Well for Growth in 2023: Here's Why
Vertex Pharmaceuticals (VRTX) stock is likely to be driven by several catalysts this year. Multiple clinical milestones are likely to be achieved in 2023 and 2024, both in its CF and non-CF portfolio.
CNW GroupAbbVie Announces Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia under the Non-Insured Health Benefits (NIHB) Program
AbbVie (NYSE: ABBV), today announced that VRAYLAR is now listed as a Limited Use product on the formulary of the Non-Insured Health Benefits (NIHB)1 program for the treatment of schizophrenia.
Motley Fool$300 a Month in These 3 Stocks Could Make You a Millionaire by Retirement
What is the link between the theoretical physicist Albert Einstein and investing? Investing as little as $300 a month into the stock market at its historical annual total return rate of 10% for 35 years is enough to start from nothing and become a millionaire. AbbVie (NYSE: ABBV) is best known for its smash-hit immunology therapy Humira.
- Simply Wall St.
AbbVie (NYSE:ABBV) shareholders have earned a 18% CAGR over the last three years
While AbbVie Inc. ( NYSE:ABBV ) shareholders are probably generally happy, the stock hasn't had particularly good run...
Motley FoolWhy AbbVie and Amgen Are Moving Lower Today
Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. The big loss came after Coherus Biosciences announced a partnership with billionaire Mark Cuban's pharmaceuticals start-up -- known as the Mark Cuban Cost Plus Drug Company -- to sell a biosimilar (a generic biologic) version of AbbVie's flagship anti-inflammatory medication, Humira, at an 85% discount. Coherus' biosimilar will be branded as Yusimry.
ZacksAstraZeneca (AZN) Discontinues Brazikumab Development
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
- Reuters
UPDATE 2-Coherus BioSciences to launch Humira biosimilar at 85% discount
Coherus BioSciences Inc said on Thursday it plans to launch a biosimilar of AbbVie Inc's Humira in July at a list price of $995 per carton, representing a discount of about 85% from the blockbuster arthritis drug. The annual cost of the biosimilar, branded as Yusimry, will be around $13,000, compared with $90,000 for Humira, Coherus said. Coherus has also partnered with Billionaire entrepreneur Mark Cuban's pharmaceuticals startup to sell the biosimilar at $569.27 plus dispensing and shipping fees.
- Reuters
UPDATE 1-AstraZeneca to stop developing Crohn's disease drug
British drugmaker AstraZeneca said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The company said the discontinuation was due to a delay in the drug's development timeline, affected by global events and "the context of a competitive landscape". AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie's $63 billion tie-up with Allergan.
ZacksAbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
- Simply Wall St.
Is AbbVie Inc.'s (NYSE:ABBV) ROE Of 57% Impressive?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Motley Fool2 Dividend Kings on Sale That Are Yielding More Than 4%
Dividend Kings have excellent track records for dividend growth, and are often seen as some of the safest income investments to own. Two dividend growth stocks that may look tempting and that investors may want to take a closer look at today are AbbVie (NYSE: ABBV) and 3M (NYSE: MMM). Healthcare company AbbVie pays a dividend yield of 4.1%, which is more than double the S&P 500 average of 1.7%.
Motley Fool2 Top Dividend Kings to Buy for the Long Haul
Last year revealed the importance of having safe stocks in your portfolio during times of market volatility. Enter dividend stocks. What's better than companies that have a track record of consistently paying and increasing dividends?
ZacksThe Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group
AbbVie, Intel, Qualcomm, Regeneron and CME Group are included in this Analyst Blog.
ZacksTop Research Reports for AbbVie, Intel & Qualcomm
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corporation (INTC) and Qualcomm Inc. (QCOM).
ZacksIronwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6%
Ironwood (IRWD) offers to acquire VectivBio, which will help strengthen its gastrointestinal treatment portfolio.
ZacksAbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
ReutersIronwood bulks up on digestive therapies with $1.15 billion VectivBio buy
(Reuters) -Ironwood Pharmaceuticals Inc said on Monday it would buy Switzerland-based drug developer VectivBio Holding AG for $1.15 billion, adding a promising treatment for digestive disorders to its portfolio. Ironwood has offered $17 per share for VectivBio, a premium of about 43% to the stock's last close. VectivBio's shares were at $16.21 in morning trade, while Ironwood's stock fell 4.5% to $10.
- Simply Wall St.
Is There An Opportunity With AbbVie Inc.'s (NYSE:ABBV) 43% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, AbbVie fair value estimate is US$255 AbbVie's US$145 share...
Motley Fool3 Relatively Safe Stocks to Buy if a Recession Is on the Way
Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a safe stock right now.
Motley Fool3 No-Brainer Dividend Stocks to Buy With $1,000 Right Now
This condition can easily occur when selecting dividend stocks. Here are three no-brainer dividend stocks to buy with $1,000 right now. Brookfield Renewable Partners (NYSE: BEP) (NYSE: BEPC) offers a distribution yield of over 4.2% for its limited partnership shares (traded under the BEP ticker) and over 3.8% for its corporate shares (traded under the BEPC ticker).
- Reuters
UPDATE 3-U.S. FDA approves Genmab-AbbVie's blood cancer therapy
The U.S. Food and Drug Administration has approved AbbVie Inc and Danish drugmaker Genmab's blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday. The therapy, epcoritamab, which will be sold under the brand name Epkinly, treats a type of advanced large B-cell lymphoma, a cancer that starts in white blood cells. It is the first-of-its-kind therapy to be approved by the FDA for the disease which annually affects 150,000 people globally.
ZacksAbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
